Latest News and Press Releases

LOS ANGELES, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors that a class action has been filed on...

LOS ANGELES, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors that a class action has been filed on...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4”...

SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that...

STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...

STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...

Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...

STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...

STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...